Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 94665 | 3.805 |
09:34 ET | 53031 | 3.805 |
09:36 ET | 15599 | 3.775 |
09:38 ET | 19982 | 3.755 |
09:39 ET | 15047 | 3.77 |
09:41 ET | 6865 | 3.75 |
09:43 ET | 17726 | 3.745 |
09:45 ET | 4179 | 3.745 |
09:48 ET | 18338 | 3.745 |
09:50 ET | 32503 | 3.755 |
09:52 ET | 20218 | 3.755 |
09:54 ET | 31511 | 3.765 |
09:56 ET | 12142 | 3.755 |
09:57 ET | 10172 | 3.745 |
09:59 ET | 1391 | 3.745 |
10:01 ET | 3800 | 3.7497 |
10:03 ET | 24417 | 3.755 |
10:06 ET | 22238 | 3.73 |
10:08 ET | 44022 | 3.725 |
10:10 ET | 8796 | 3.72 |
10:12 ET | 114596 | 3.74 |
10:14 ET | 15672 | 3.73 |
10:15 ET | 10882 | 3.72 |
10:17 ET | 32444 | 3.72 |
10:19 ET | 14980 | 3.715 |
10:21 ET | 9436 | 3.71 |
10:24 ET | 44568 | 3.695 |
10:26 ET | 8238 | 3.695 |
10:28 ET | 46903 | 3.7 |
10:30 ET | 32641 | 3.695 |
10:32 ET | 8555 | 3.7009 |
10:33 ET | 5448 | 3.705 |
10:35 ET | 22144 | 3.705 |
10:37 ET | 20803 | 3.69 |
10:39 ET | 57766 | 3.685 |
10:42 ET | 11029 | 3.68 |
10:44 ET | 46625 | 3.7018 |
10:46 ET | 20685 | 3.685 |
10:48 ET | 10377 | 3.7 |
10:50 ET | 7486 | 3.705 |
10:51 ET | 12219 | 3.69 |
10:53 ET | 5218 | 3.695 |
10:55 ET | 7837 | 3.69 |
10:57 ET | 20042 | 3.7 |
11:00 ET | 3800 | 3.71 |
11:02 ET | 10283 | 3.705 |
11:04 ET | 18243 | 3.695 |
11:06 ET | 9678 | 3.705 |
11:08 ET | 3100 | 3.7 |
11:09 ET | 7894 | 3.695 |
11:11 ET | 1582 | 3.695 |
11:13 ET | 5958 | 3.695 |
11:15 ET | 2857 | 3.69 |
11:18 ET | 2971 | 3.69 |
11:20 ET | 6113 | 3.69 |
11:22 ET | 3199 | 3.695 |
11:24 ET | 28875 | 3.7097 |
11:26 ET | 10197 | 3.6988 |
11:27 ET | 2656 | 3.695 |
11:29 ET | 32037 | 3.695 |
11:31 ET | 5522 | 3.69 |
11:33 ET | 2586 | 3.69 |
11:36 ET | 7091 | 3.695 |
11:38 ET | 3250 | 3.695 |
11:40 ET | 3500 | 3.695 |
11:42 ET | 161775 | 3.705 |
11:44 ET | 30619 | 3.705 |
11:45 ET | 59078 | 3.72 |
11:47 ET | 44188 | 3.745 |
11:49 ET | 36525 | 3.745 |
11:51 ET | 53592 | 3.745 |
11:54 ET | 34731 | 3.735 |
11:56 ET | 7942 | 3.74 |
11:58 ET | 25443 | 3.74 |
12:00 ET | 5937 | 3.735 |
12:02 ET | 48521 | 3.73 |
12:03 ET | 53092 | 3.735 |
12:05 ET | 2971 | 3.735 |
12:07 ET | 6271 | 3.73 |
12:09 ET | 4800 | 3.735 |
12:12 ET | 5471 | 3.735 |
12:14 ET | 53747 | 3.725 |
12:16 ET | 55004 | 3.7 |
12:18 ET | 23180 | 3.705 |
12:20 ET | 2335 | 3.7 |
12:21 ET | 3755 | 3.7 |
12:23 ET | 12708 | 3.7 |
12:25 ET | 11092 | 3.7 |
12:27 ET | 15200 | 3.7 |
12:30 ET | 42036 | 3.7054 |
12:32 ET | 4379 | 3.7087 |
12:34 ET | 17001 | 3.695 |
12:36 ET | 3891 | 3.695 |
12:38 ET | 2528 | 3.695 |
12:39 ET | 26854 | 3.705 |
12:41 ET | 19288 | 3.705 |
12:43 ET | 70236 | 3.695 |
12:45 ET | 3076 | 3.69 |
12:48 ET | 14064 | 3.7 |
12:50 ET | 24286 | 3.705 |
12:52 ET | 15223 | 3.7 |
12:54 ET | 1170 | 3.705 |
12:56 ET | 4807 | 3.705 |
12:57 ET | 4482 | 3.705 |
12:59 ET | 20471 | 3.705 |
01:01 ET | 91513 | 3.715 |
01:03 ET | 8127 | 3.7 |
01:06 ET | 2600 | 3.7 |
01:08 ET | 23589 | 3.7001 |
01:10 ET | 11176 | 3.7 |
01:12 ET | 5471 | 3.695 |
01:14 ET | 13291 | 3.691 |
01:15 ET | 4236 | 3.695 |
01:17 ET | 1964 | 3.69 |
01:19 ET | 11885 | 3.69 |
01:21 ET | 61219 | 3.705 |
01:24 ET | 2503 | 3.71 |
01:26 ET | 23518 | 3.71 |
01:28 ET | 25570 | 3.71 |
01:30 ET | 13308 | 3.73 |
01:32 ET | 1560 | 3.725 |
01:33 ET | 2542 | 3.73 |
01:35 ET | 8442 | 3.725 |
01:37 ET | 4300 | 3.725 |
01:39 ET | 20137 | 3.719 |
01:42 ET | 7300 | 3.72 |
01:44 ET | 37722 | 3.72 |
01:46 ET | 15194 | 3.73 |
01:48 ET | 1400 | 3.73 |
01:50 ET | 11542 | 3.73 |
01:51 ET | 9074 | 3.725 |
01:53 ET | 4589 | 3.725 |
01:55 ET | 5492 | 3.72 |
01:57 ET | 4193 | 3.725 |
02:00 ET | 3576 | 3.73 |
02:02 ET | 3779 | 3.725 |
02:04 ET | 6648 | 3.73 |
02:06 ET | 4610 | 3.725 |
02:08 ET | 5338 | 3.72 |
02:09 ET | 2091 | 3.72 |
02:11 ET | 10505 | 3.73 |
02:13 ET | 58966 | 3.745 |
02:15 ET | 8417 | 3.7499 |
02:18 ET | 8176 | 3.745 |
02:20 ET | 28319 | 3.755 |
02:22 ET | 81312 | 3.75 |
02:24 ET | 31556 | 3.75 |
02:26 ET | 2921 | 3.755 |
02:27 ET | 7402 | 3.755 |
02:29 ET | 9621 | 3.755 |
02:31 ET | 4624 | 3.755 |
02:33 ET | 7705 | 3.755 |
02:36 ET | 27176 | 3.755 |
02:38 ET | 1300 | 3.755 |
02:40 ET | 7628 | 3.75 |
02:42 ET | 47609 | 3.745 |
02:44 ET | 19551 | 3.73 |
02:45 ET | 13832 | 3.73 |
02:47 ET | 5685 | 3.735 |
02:49 ET | 10979 | 3.735 |
02:51 ET | 7753 | 3.735 |
02:54 ET | 29070 | 3.75 |
02:56 ET | 9597 | 3.75 |
02:58 ET | 1777 | 3.75 |
03:00 ET | 9027 | 3.745 |
03:02 ET | 10016 | 3.74 |
03:03 ET | 13596 | 3.745 |
03:05 ET | 4843 | 3.745 |
03:07 ET | 46335 | 3.75 |
03:09 ET | 15556 | 3.73 |
03:12 ET | 56807 | 3.73 |
03:14 ET | 36453 | 3.7238 |
03:16 ET | 5107 | 3.73 |
03:18 ET | 9844 | 3.725 |
03:20 ET | 26309 | 3.735 |
03:21 ET | 59871 | 3.725 |
03:23 ET | 3800 | 3.725 |
03:25 ET | 9117 | 3.725 |
03:27 ET | 15274 | 3.725 |
03:30 ET | 8998 | 3.72 |
03:32 ET | 4237 | 3.725 |
03:34 ET | 13741 | 3.725 |
03:36 ET | 21497 | 3.71 |
03:38 ET | 8426 | 3.7101 |
03:39 ET | 14577 | 3.7 |
03:41 ET | 26696 | 3.705 |
03:43 ET | 25251 | 3.705 |
03:45 ET | 71546 | 3.72 |
03:48 ET | 55095 | 3.72 |
03:50 ET | 31932 | 3.72 |
03:52 ET | 73825 | 3.725 |
03:54 ET | 116320 | 3.725 |
03:56 ET | 73153 | 3.72 |
03:57 ET | 295811 | 3.685 |
03:59 ET | 365247 | 3.68 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.2B | -10.6x | --- |
Vera Therapeutics Inc | 2.2B | -20.0x | --- |
Dyne Therapeutics Inc | 2.3B | -7.1x | --- |
Rocket Pharmaceuticals Inc | 2.1B | -8.2x | --- |
Keros Therapeutics Inc | 1.9B | -10.3x | --- |
Recursion Pharmaceuticals Inc | 2.3B | -6.2x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.2B |
---|---|
Revenue (TTM) | $520.0K |
Shares Outstanding | 593.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.44 |
EPS | $-0.35 |
Book Value | $0.46 |
P/E Ratio | -10.6x |
Price/Sales (TTM) | 4,266.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40,381.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.